Jennifer J.D. Morrissette, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Clinical Director, Center for Personalized Diagnostics
University of Pennsylvania Perelman School of Medicine
Contact InformationDepartment of Pathology and Laboratory Medicine
3020 Market Street, Suite 220
Philadelphia, PA 19104
Office: 215-898-5578
Fax: 215-898-9817
Email: jemorris@pennmedicine.upenn.edu
Specialty Division
Precision and Computational Diagnostics
Education
B.S. (Molecular Biology), State University of New York at Buffalo, 1986
Ph.D. (Molecular Genetics), State University of New York at Buffalo, 1992
Specialty Certification
American Board of Medical Genetics, Clinical Molecular Genetic Diagnostics, 2002
American Board of Medical Genetics, Clinical Cytogenetics, 2002
New York State Certificate of Qualification,
Cytogenetics and Molecular Genetic Diagnostics, 2004
Postgraduate Training
Postdoctoral Fellow, Molecular Genetics, Department of Pathology, Harvard Medical School, Boston MA, 1992-1997
Fellow in Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 1998-2002
Awards and Honors
Mark Diamond Initiative Award, Department of Biological Sciences, State University of New York at Buffalo, 1990
NIH Intramural Research Training Award fellowship, 1992-1993
Pathobiology of Cancer: The Edward A. Smuckler Memorial Workshop, Keystone Colorado, American Association of Cancer Research, 1992
American Social Health Association/Burroughs Wellcome Fund Research Fellowship, 1994-1996
American Association of Cancer Research Fellowship, 1996-1997
General Clinical Research Center (GCRC). Children’s Hospital of Philadelphia, Investigator, 2001-2005
Foerderer Fund for Excellence, Molecular and Cytogenetic Analysis of Autism, 2003-2004
Peter C. Nowell Award in Pathology, University of Pennsylvania, 2013
Memberships and Professional Organizations
American Society Human Genetics, 1998 - Present
Philadelphia Genetics Group, 2004 - 2018
American College of Medical Genetics, 2005 - Present
American Cytogenetics Conference, 2006 - Present
Association of Molecular Pathology, 2011 - Present
American Society for Clinical Pathology (ASCP) Immuno-Oncology Working Group, 2018 - Present
International Federation of Clinical Chemistry and Laboratory Medicine, 2019 - Present
Web Links
Selected Publications
NTRK point mutations and their functional consequences.
Rogers C, Morrissette JJD, Sussman RT., Cancer Genet. 262-263(): 5-15, 2022, PMID:34972036
Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
Lim TL, Lieberman DB, Davis AR, Loren AW, Hausler R, Bigdeli A, Li Y, Powers J, Raper A, Regeneron Genetics Center, Carty SA, Nathanson KL, Bagg A, Hexner EO, Maxwell KN, Morrissette JJD, Babushok DV, Leukemia. 36(): 283-287, 2022, PMID:34193977
Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML
Sussman RT, Manning B, Ackerman D, Bigdeli A, Pammer P, Velu PD, Luger SM, Bagg A, Carroll M, Morrissette JJD, Cancer Genet, 2021
Developing an Academic Consortium for Shared Bioinformatics & Concordance Data
Morrissette, JJD, Oxford Global Virtual Meeting, 2021
Clinical validation of a rapid NGS-based molecular screening assay for myeloid neoplasm
Sande C, Sussman R, Wu R, Morrissette JJD, Lim MS, Elenitoba-Johnson KS, Association for Molecular Pathology, 2021
Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice
Davis AR, Stone SL, Oran AR, Sussman RT, Bhattacharyya S, Morrissette JJD, Bagg A., Mod Pathol., 2020, PMID:33311649
Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia
Nelson ND, McMahon CM, El-Sharkawy Navarro F, Freyer CW, Roth JJ, Luger SM, Bagg A, Morrissette JJD., Br J Haematol 191(): , 2020, PMID:33460058
Experience with an RNA fusion transcript panel for detection of potential therapeutic targets in gliomas
Kothari S, Bagley S, Desai A, Morrissette JJD, Sussman R, Nasrallah M, Society For Neuro-Oncology Annual Conference, 2020
Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets.
Paul MR, Pan TC, Pant DK, Shih NN, Chen Y, Harvey KL, Solomon A, Lieberman D, Morrissette JJ, Soucier-Ernst D, Goodman NG, Stavropoulos SW, Maxwell KN, Clark C, Belka GK, Feldman M, DeMichele A, Chodosh LA., J Clin Invest 130(): 4252-4265, 2020, PMID:32657779
Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia
Hurwitz SN, Caponetti GC, Smith L, Qualtieri J, Morrissette JJD, Lee WS, Frank DM, Bagg A., Am J Surg Pathol., 2020, PMID:32520760
